N-of-One Selected by Guardant Health to Provide Clinical Interpretation for Guardant360™ Tests

  • Posted by Emily Haynes
  • On May 19, 2015
  • 0 Comments
LEXINGTON, Mass., May 19, 2014 – N-of-One, the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with Guardant Health to provide clinical decision support for Guardant360™, a breakthrough blood test that enables next generation sequencing of solid tumor DNA. Financial terms of the agreement are not disclosed. Guardant360 is the […]
Read More

CellNetix Adopts N-of-One TrialMatch™, Based on N-of-One’s Leading Clinical Interpretation of NGS Tests

  • Posted by Emily Haynes
  • On May 12, 2015
  • 0 Comments
N-of-One TrialMatch™ enables clinicians to quickly identify a patient’s unique molecular eligibility for clinical trials while incorporating clinical- and geographic-specific criteria   LEXINGTON, Mass., May 12, 2015 –N-of-One, Inc., the leading provider of clinical interpretation evidence, today announced that CellNetix Pathology and Laboratories has adopted N-of-One’s new clinical trial matching solution, TrialMatch™, as well as […]
Read More

N-of-One Selected by Affymetrix to Provide High-Quality Copy Number Variation Analysis Interpretation for OncoScan® FFPE Assay Kit

  • Posted by Emily Haynes
  • On May 7, 2015
  • 0 Comments
Affymetrix empowers OncoScan assay users with actionable insights while saving them significant time and resources   LEXINGTON, Mass., May 7, 2015 – N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced that it has signed a business partner agreement with Affymetrix, a leading provider of DNA microarrays.  Under this agreement, N-of-One […]
Read More
BACK TO
TOP
LEARN
MORE